CGT encompasses a group of novel therapies involving either the manipulation of cells to improve the immune system (cell therapy), or the transfer of genetic material to treat disease (gene therapy). This opportunity addresses the manufacturing of CAR-T and gene therapies.
القطاع
الأدوية والتكنولوجيا الحيوية
تحميل الفرصة
أبرز معالم الاستثمار
- Expected Investment size of USD: 25M – 50M
- Manufacturing capacity: 500 – 5000 doses annually
- Expected IRR: 15 – 20%
- Job Creation: ~50 high skilled postgraduate level jobs (e.g., manufacturing science and tech., assay development, regulatory affairs), with average salaries of $70K+ p.a.
- GDP Impact USD: 17M2
- Location (Examples): KFSH-RC, NEOM, Dammam